Rule Summary and Fiscal Analysis (Part A)

Bureau of Workers' Compensation
Agency Name

Tom Sico
Division | Contact

30 West Spring St. L26 Columbus OH 43215-0000 | **614-466-6600** | **614-621-3372**
Agency Mailing Address (Plus Zip) | Phone | Fax

4123-6-21.3 — Rule Number

AMENDMENT — TYPE of rule filing

Rule Title/Tag Line: **Outpatient medication formulary.**

RULE SUMMARY

1. Is the rule being filed consistent with the requirements of the RC 119.032 review? **No**

2. Are you proposing this rule as a result of recent legislation? **No**

3. Statute prescribing the procedure in accordance with the agency is required to adopt the rule: **119.03**

4. Statute(s) authorizing agency to adopt the rule: **4121.12, 4121.121**

5. Statute(s) the rule, as filed, amplifies or implements: **4121.441, 4123.66**

6. State the reason(s) for proposing (i.e., why are you filing,) this rule:

BWC now proposes to revise this rule by the addition of restrictions and limitations on reimbursement for certain drugs listed in the formulary. These recommended changes are the result of recommendations from the P&T Committee and reflect BWC's dedication to providing for appropriate care while ensuring the safety of our injured workers. The committee's recommendations resulted from consideration of current literature, accepted treatment guidelines and best clinical practice as well as FDA and manufacturer's published information.

7. If the rule is an AMENDMENT, then summarize the changes and the content of the proposed rule; If the rule type is RESCISSION, NEW or NO CHANGE,

then summarize the content of the rule:

The proposed changes are:

1. Modify the coverage limitations on the skeletal muscle relaxant drug class to provide for prior authorization based approval of additional coverage for up to one year when used as adjuncts in chronic pain management and post operative recovery periods.

2. Modify the coverage limitations on the skeletal muscle relaxant drug class to provide for prior authorization based approval for tizanidine products to be used in treatment of spasticity in allowed conditions.

3. Place coverage limitations on utilization of all sustained release opiates, both in products approved and dosing schedules prescribed.

4. Remove specific sustained release opiate products from reimbursement coverage.

5. Place coverage limitations on utilization of short acting opiates, all opiate/acetaminophen and opiate/ibuprofen containing combination products approved and doses prescribed.

6. Remove specific drug combinations from reimbursement coverage.

7. Place coverage limitations on utilization of buccal and transmuccosal fentanyl products approved as well as doses prescribed.

8. Limit reimbursement for new dosage forms of existing formulary medications to those that have been approved by the P&T Committee. This limitation is subject to the medical necessity approval process described in paragraph (G) of the rule.

8. If the rule incorporates a text or other material by reference and the agency claims the incorporation by reference is exempt from compliance with sections 121.71 to 121.74 of the Revised Code because the text or other material is **generally available** to persons who reasonably can be expected to be affected by the rule, provide an explanation of how the text or other material is generally available to those persons:

This response left blank because filer specified online that the rule does not incorporate a text or other material by reference.

9. If the rule incorporates a text or other material by reference, and it was **infeasible** for the agency to file the text or other material electronically, provide an explanation of why filing the text or other material electronically was infeasible:

This response left blank because filer specified online that the rule does not incorporate a text or other material by reference.

10. If the rule is being **rescinded** and incorporates a text or other material by reference, and it was **infeasible** for the agency to file the text or other material, provide an explanation of why filing the text or other material was infeasible:

Not Applicable.

11. If **revising** or **refiling** this rule, identify changes made from the previously filed version of this rule; if none, please state so:

Not Applicable.

12. 119.032 Rule Review Date: **9/1/2016**

(If the rule is not exempt and you answered NO to question No. 1, provide the scheduled review date. If you answered YES to No. 1, the review date for this rule is the filing date.)

NOTE: If the rule is not exempt at the time of final filing, two dates are required: the current review date plus a date not to exceed 5 years from the effective date for Amended rules or a date not to exceed 5 years from the review date for No Change rules.

FISCAL ANALYSIS

13. Estimate the total amount by which *this proposed rule* would **increase / decrease** either **revenues / expenditures** for the agency during the current biennium (in dollars): Explain the net impact of the proposed changes to the budget of your agency/department.

This will have no impact on revenues or expenditures.

0.00

N/A

14. Identify the appropriation (by line item etc.) that authorizes each expenditure necessitated by the proposed rule:

N/A

15. Provide a summary of the estimated cost of compliance with the rule to all directly affected persons. When appropriate, please include the source for your information/estimated costs, e.g. industry, CFR, internal/agency:

N/A

16. Does this rule have a fiscal effect on school districts, counties, townships, or municipal corporations? **No**

17. Does this rule deal with environmental protection or contain a component dealing with environmental protection as defined in R. C. 121.39? **No**